menu search

Why kura sushi stock dropped almost 14% last month

Kura Sushi stock went down after comments from analysts shook investor confidence. The company is growi...

November 2, 2023, 4:46 pm

Verbal intervention keeps yen from falling further, at least for now

A more dovish take by the BOJ yesterday and then the purported absence of Tokyo intervention in October gave the green light for USD/JPY to march high...

November 1, 2023, 4:59 am

Why fisker stock pulled back today

Warnings from two separate companies shook Fisker and other EV stocks. Just last week, Fisker cut price...

October 30, 2023, 6:13 pm

Baselode energy says latest assays at ackio zone show uranium mineralization shows no signs of fading

Baselode Energy Corp (TSX-V:FIND, OTCQB:BSENF) told investors that additional assay results from the ACKIO high-grade uranium zone on its ...

October 30, 2023, 8:16 am

Barnes group inc. (b) q3 2023 earnings call transcript

Barnes Group Inc. (NYSE:B ) Q3 2023 Earnings Conference Call October 27, 2023 8:30 AM ET Company Participants Bill Pitts - Vice President, Investor Re...

October 27, 2023, 2:19 pm

Meta sued over features that hook children to instagram, facebook

More than three dozen states and the District of Columbia accused the tech giant of knowingly using addictive features to draw in and retain children ...

October 24, 2023, 12:09 pm

Adriatic metals stockpiling ore ahead of vares opening

Adriatic Metals said will continue to stockpile ore while it completes final commissioning of the processing plant at its Vares silver mine developme...

October 24, 2023, 2:41 am

hookipa pharma presents additional preliminary phase 2 data on hb-200 in combination with pembrolizumab as first-line treatment in patients with hpv16+ head and neck cancers at european society for me

42 percent objective response rate (ORR) was observed among 19 evaluable patients with recurrent/metastatic head and neck cancer in the first-line set...

October 22, 2023, 10:01 am

hookipa pharma presents additional preliminary phase 2 data on hb-200 in combination with pembrolizumab as first-line treatment in patients with hpv16+ head and neck cancers at european society for me

42 percent objective response rate (ORR) was observed among 19 evaluable patients with recurrent/metastatic head and neck cancer in the first-line set...

October 22, 2023, 10:01 am

hookipa pharma presents additional preliminary phase 2 data on hb-200 in combination with pembrolizumab as first-line treatment in patients with hpv16+ head and neck cancers at european society for me

42 percent objective response rate (ORR) was observed among 19 evaluable patients with recurrent/metastatic head and neck cancer in the first-line set...

October 22, 2023, 10:01 am

hookipa pharma presents additional preliminary phase 2 data on hb-200 in combination with pembrolizumab as first-line treatment in patients with hpv16+ head and neck cancers at european society for me

42 percent objective response rate (ORR) was observed among 19 evaluable patients with recurrent/metastatic head and neck cancer in the first-line set...

October 22, 2023, 10:01 am

hookipa pharma presents additional preliminary phase 2 data on hb-200 in combination with pembrolizumab as first-line treatment in patients with hpv16+ head and neck cancers at european society for me

42 percent objective response rate (ORR) was observed among 19 evaluable patients with recurrent/metastatic head and neck cancer in the first-line set...

October 22, 2023, 10:01 am

hookipa pharma presents additional preliminary phase 2 data on hb-200 in combination with pembrolizumab as first-line treatment in patients with hpv16+ head and neck cancers at european society for me

42 percent objective response rate (ORR) was observed among 19 evaluable patients with recurrent/metastatic head and neck cancer in the first-line set...

October 22, 2023, 10:01 am

hookipa pharma presents additional preliminary phase 2 data on hb-200 in combination with pembrolizumab as first-line treatment in patients with hpv16+ head and neck cancers at european society for me

42 percent objective response rate (ORR) was observed among 19 evaluable patients with recurrent/metastatic head and neck cancer in the first-line set...

October 22, 2023, 10:01 am

hookipa pharma presents additional preliminary phase 2 data on hb-200 in combination with pembrolizumab as first-line treatment in patients with hpv16+ head and neck cancers at european society for me

42 percent objective response rate (ORR) was observed among 19 evaluable patients with recurrent/metastatic head and neck cancer in the first-line set...

October 22, 2023, 10:01 am

hookipa pharma presents additional preliminary phase 2 data on hb-200 in combination with pembrolizumab as first-line treatment in patients with hpv16+ head and neck cancers at european society for me

42 percent objective response rate (ORR) was observed among 19 evaluable patients with recurrent/metastatic head and neck cancer in the first-line set...

October 22, 2023, 10:01 am

hookipa pharma presents additional preliminary phase 2 data on hb-200 in combination with pembrolizumab as first-line treatment in patients with hpv16+ head and neck cancers at european society for me

42 percent objective response rate (ORR) was observed among 19 evaluable patients with recurrent/metastatic head and neck cancer in the first-line set...

October 22, 2023, 10:01 am

hookipa pharma presents additional preliminary phase 2 data on hb-200 in combination with pembrolizumab as first-line treatment in patients with hpv16+ head and neck cancers at european society for me

42 percent objective response rate (ORR) was observed among 19 evaluable patients with recurrent/metastatic head and neck cancer in the first-line set...

October 22, 2023, 10:01 am

hookipa pharma presents additional preliminary phase 2 data on hb-200 in combination with pembrolizumab as first-line treatment in patients with hpv16+ head and neck cancers at european society for me

42 percent objective response rate (ORR) was observed among 19 evaluable patients with recurrent/metastatic head and neck cancer in the first-line set...

October 22, 2023, 10:01 am

hookipa pharma presents additional preliminary phase 2 data on hb-200 in combination with pembrolizumab as first-line treatment in patients with hpv16+ head and neck cancers at european society for me

42 percent objective response rate (ORR) was observed among 19 evaluable patients with recurrent/metastatic head and neck cancer in the first-line set...

October 22, 2023, 10:01 am


Search within

Pages Search Results: